
Pohlmann PR, Yau C, DeMichele A, et al.
Amsterdam 70-gene profile (MammaPrint) Low Risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P6-10-06
.
abstractdoi link

poster (pdf)
slides (pdf)

Li W, Onishi N, Newitt DC, et al.
The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P6-02-01
.
abstractdoi link

poster (pdf)
slides (pdf)

Venters SJ, Wolf DM, Brown-Swigart L, et al.
Assessing biomarkers to inform treatment de-escalation: mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P6-10-02
.
abstractdoi link

poster (pdf)
slides (pdf)

Magbanua MM, Brown-Swigart L, Hirst G, et al.
Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in highrisk early stage breast cancer reflects response and risk of metastatic recurrence
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P5-01-04
.
abstractdoi link

poster (pdf)
slides (pdf)

Ghersin H, Chattopadhyay A, Blaes A, et al.
Introducing an electronic platform to collect patient reported outcomes in the I-SPY 2 TRIAL, a neoadjuvant clinical trial
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
OT3-19-02
.
abstractdoi link

poster (pdf)
slides (pdf)

Yau C, van der Noordaa M, Wei J, et al.
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
GS5-01
.
abstractdoi link

poster (pdf)
slides (pdf)

Wolf DM, Yau C, Wulfkuhle J, et al.
HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P4-10-02
.
abstractdoi link

poster (pdf)
slides (pdf)

Sayaman RW, Wolf DM, Yau C, et al.
Application of Machine Learning to elucidate the biology predicting response in the I‑SPY 2 neoadjuvant breast cancer trial
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P1-21-08
.
abstractdoi link

poster (pdf)
slides (pdf)

Onishi N, Li W, Newitt DC, et al.
Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
PD9-05
.
abstractdoi link

poster (pdf)
slides (pdf)

Li W, Onishi N, Newitt DC, et al.
Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
PD9-04
.
abstractdoi link

poster (pdf)
slides (pdf)

Arasu V, Kim P, Li W, et al.
Additive benefit of MRI background parenchymal enhancement (BPE) to an MRI tumor volume model for predicting pathologic complete response (pCR) to neoadjuvant treatment in I-SPY2
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
PD9-06
.
abstractdoi link

poster (pdf)
slides (pdf)

Osdoit M, Yau C, Symmans WF, et al.
The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P3-08-16
.
abstractdoi link

poster (pdf)
slides (pdf)

Helsten TL, Lo SS, Yau C, et al.
Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P3-11-02
.
abstractdoi link

poster (pdf)
slides (pdf)

Liu MC, Robinson PA, Yau C, et al.
Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk early-stage HER2-negative breast cancer: Results from the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P3-09-02
.
abstractdoi link

poster (pdf)
slides (pdf)

Basu A, Philip EJ, Dewitt B, et al.
The Clinical Benefit Index: A Pilot Study Integrating Treatment Efficacy and Quality of Life in Oncology Clinical Trials
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P2-12-06
.
abstractdoi link

poster (pdf)
slides (pdf)

Yau C, Symmans W, Pusztai L, et al.
Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P2-20-02
.
abstractdoi link

poster (pdf)
slides (pdf)

Du L, Yau C, Brown-Swigart L, et al.
Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2- negative (HR+/HER2-) breast cancer
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
;
(
)
; Abstract No.
P2-11-04
.
abstractdoi link

poster (pdf)
slides (pdf)

Campbell MJ, Yau C, Bolen J, et al.
Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL
.
AACR Annual Meeting
,
Mar 29 - APr 3
,
2019
. In:
Cancer Res
2019
;
79
(
13 Suppl
)
; Abstract No.
CT003
.
abstractdoi link

poster (pdf)
slides (pdf)

Li W, Newitt DC, Wilmes LJ, et al
Combination of MRI quantitative measures improves prediction of residual disease following neoadjuvant chemotherapy (NAC) for breast cancer in the I-SPY 2 TRIAL
.
ISMRM 27th Annual Meeting
,
May 11-16
,
2019
. In:
;
(
)
; Abstract No.
0278
.
abstractdoi link

poster (pdf)
slides (pdf)

Wulfkuhle JD, Yau C, Wolf D, et al.
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial
.
2019 ASCO Annual Meeting
,
May 30 - June 4
,
2019
. In:
J Clin Oncol
2019
;
37
(
15
)
; Abstract No.
2631
.
abstractdoi link

poster (pdf)
slides (pdf)

Wolf DM, Yau C, Wulfkuhle J, et al.
Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial
.
AACR Annual Meeting 2019
,
Mar 29 - Apr 3
,
2019
. In:
Cancer Res
2019
;
79
(
13 Suppl
)
; Abstract No.
2679
.
abstractdoi link

poster (pdf)
slides (pdf)

Yau C, van der Noordaa M, Wei J, et al
Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis
.
2019 San Antonio Breast Cancer Symposium
,
December 10-14
,
2019
. In:
Cancer Research
2020
;
80
(
4_Supplement
)
; Abstract No.
GS5-01
.
abstractdoi link

poster (pdf)
slides (pdf)